New First-line Immunotherapy-based Therapies for Unresectable Hepatocellular Carcinoma: A Living Network Meta-analysis.

J Clin Transl Hepatol · 2024 · PMC10794275 · PMID 38250466

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

For HCC patients with HBV, atezolizumab plus bevacizumab provided a numerical trend toward better OS than most of the treatments and conferred a similar survival benefit when compared to other combination therapies ( Supplementary Fig. 18 ).

also in 273 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.